With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...

Apple stock has tumbled at the start of the year. BofA Securities advises investors to stay the course but joined a chorus of Wall Street voices expressing concern over flagging iPhone demand. The ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and with caution. As the creator of the blockbuster weight-loss drug Zepbound, and ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...